US OptionsDetailed Quotes
INSM240517C35000
- 0.05
- 0.000.00%
15min DelayClose May 17 10:45 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume473 Open Interest35.00Strike Price0.00Turnover2272.82%IV41.50%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.0311Delta0.0160Gamma495.40Leverage Ratio-6.4442Theta0.0000Rho15.42Eff Leverage0.0001Vega
Insmed Stock Discussion
Sign in to post a comment
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
10
1
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
The Wells Fargo equity team identified 14 high-conviction, catalyst-driven stock opportunities for the second quarter, including two Magnificent 7 names: Amazon and Tesla.
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$Amazon(AMZN.US$ , $Annexon(ANNX.US$ ,...
The list, updated each quarter, indicates where analysts "see significant Q2 24 catalysts that could drive meaningful upside or downside."
The list includes 10 Long (or Overweight) trades and 4 Short (or Underweight) trades:
$Amazon(AMZN.US$ , $Annexon(ANNX.US$ ,...
10
1
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
Insiders at Insmed selling shares may indicate they believe the shares are overpriced. Some alignment exists between management and smaller shareholders, but lack of recent insider buying and net selling over the past year raises concerns.
1
Insmed's overvaluation and slower than average forecasted revenue growth raise investors' concern. Despite hopes for a turnaround, analysts express less confidence, indicating risks for shareholders and potential investors.
JP Morgan predicts growth for Insmed due to recent study updates, potential rise of Denali shares ahead of 2025 readouts, and an upside for Immunocore shares following a 'strong' oncology drug launch. Crinetics could also benefit from upcoming catalysts.
Considering the strong revenue growth, if this trend continues, the share price could follow. Insmed's recent upturn in shareholder returns is seen as a sign of business improvement.
1
Gainers:
• $National CineMedia(NCMI.US$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor(MX.US$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal(DLO.US$ +13.7% (In reaction to earnings)
• $SiriusPoint(SPNT.US$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air(XAIR.US$ +6.4% (presents positive study update from the at-home LungF...
• $National CineMedia(NCMI.US$ +17.9% (AMC discloses 6.8% stake in NCMI)
• $MagnaChip Semiconductor(MX.US$ +14.8% (report that private equity firms including Carlyle Group (CG) will bid for the company)
• $DLocal(DLO.US$ +13.7% (In reaction to earnings)
• $SiriusPoint(SPNT.US$ +8.2% (Chairman and CEO resigns to pursue other opportunities)
• $Beyond Air(XAIR.US$ +6.4% (presents positive study update from the at-home LungF...
14
1
Upgrades
• $Ares Capital Corp(ARCC.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $22
• $Avery Dennison(AVY.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $195
• $Avery Dennison(AVY.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $195 (from $215)
• $Brookfield Asset Management(BAM.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $71.50 (from $68)
• $Ecolab(ECL.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $1...
• $Ares Capital Corp(ARCC.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $22
• $Avery Dennison(AVY.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $195
• $Avery Dennison(AVY.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $195 (from $215)
• $Brookfield Asset Management(BAM.US$ : Credit Suisse Upgrades to Outperform from Neutral - PT $71.50 (from $68)
• $Ecolab(ECL.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $1...
14
No comment yet
Jimmy1819 : have you been investing professionally or as a hobby?